Klin Farmakol Farm. 2008;22(2):64-67

Targeted therapy in oncology

Jozef Mardiak
Národný onkologický ústav, Bratislava

The mechanisms of action of targeted therapy differ from those of traditional cytotoxic chemotherapy. Traditional chemotherapy targets rapidly dividing cells, including cancer cells as well as certain normal tissues. By contrast, targeted therapy blocks the proliferation of cancer cells by interfering with specific molecules required for tumor development and growth. The molecular pathways most often targeted in the treatment of malignant disease are the cell surface antigens, vascular endothelial growth factor, epidermal growth factor receptor and some genetically defined abnormalities. Targeted treatment which includes monoclonal antibodies and small molecule inhibitors has markedly changed the outcomes of chronic myeloid leukemia, gastrointestinal stromal tumors, non-Hodgkin´s lymphoma, renal cancer, colorectal cancer, and breast cancer. The tolerance of targeted therapy is generally better than that of traditional chemotherapy, however, it is associated with severe side effects such as cardiac dysfunction, hypertension, thrombosis, proteinuria, and acneiform rash. Targeted treatment has also raised a lot of new question about the biology of tumors and the tailoring of cancer treatment to an individual patient.

Keywords: Key words: targeted therapy, monoclonal antibodies, small molecules.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mardiak J. Targeted therapy in oncology. Klin Farmakol Farm. 2008;22(2):64-67.
Download citation

References

  1. Tobinai K. Rituximab and other emerging monoclonal antibody therapies for lymphoma. Expert Opin Emerg Drugs. 2002 Oct; 7 (2): 289-302. Go to original source... Go to PubMed...
  2. Kantarjian HM, Cortes JE, O' Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003; 101 (1): 97-100. Go to original source... Go to PubMed...
  3. Verweij J, Casali PG, Zalcherg J, et al. Progression-free survival in gastrointestinal stroma tumours with high dose imatinib: randomised trial. Lancet 2004; 364: 1127. Go to original source... Go to PubMed...
  4. Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 1-18. Go to original source... Go to PubMed...
  5. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006; 33 (4): 369-385. Go to original source... Go to PubMed...
  6. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006; 55 (4): 657-670. Go to original source... Go to PubMed...
  7. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001; 19 (13): 3267-3279. Go to original source... Go to PubMed...
  8. Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 2007: 317-23. Go to original source... Go to PubMed...
  9. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005; 23 (9): 1147-1157. Go to original source... Go to PubMed...
  10. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6 (9): 714-727. Go to original source... Go to PubMed...
  11. Kantarjian H, Sawyers C, Hochhaus A, et al., for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346 (9): 645-652. Go to original source... Go to PubMed...
  12. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007 Oct 10; 25 (29): 4536-4541. Go to original source... Go to PubMed...
  13. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004 Mar 1; 22 (5): 785-794. Go to original source... Go to PubMed...
  14. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. J Clin oncol 2004; 22: 7010. Go to original source...
  15. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003; 9 (6): 685-693. Go to original source... Go to PubMed...
  16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351 (4): 337-345. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.